Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30947602 | 0.83 | NOS3 (0.39) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL13971495 | 0.83 | NOS3 (0.39) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL18745357 | 0.81 | MAPK1 (0.40) | ALDH1A1TDP1KMT2AMAPTMEN1 | |
| SCHEMBL21972604 | 0.79 | ESR1 (0.38) | ALDH1A1KMT2AMEN1GAAADRB2 | |
| SCHEMBL26428605 | 0.77 | KIF11 (0.38) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL30947607 | 0.77 | NOS3 (0.57) | ALDH1A1GAAKIF11KDM4ENOS3 | |
| SCHEMBL1660106 | 0.77 | NOS3 (0.57) | ALDH1A1GAAKIF11KDM4ENOS3 | |
| SCHEMBL8764962 | 0.77 | TSHR (0.38) | RECQLNOS3NOS2 | |
| SCHEMBL347025 | 0.76 | CCR1 (0.48) | ALDH1A1HPGDALOX15HSD17B10TDP1 | |
| SCHEMBL29453375 | 0.76 | CCR1 (0.48) | ALDH1A1HPGDALOX15HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043613-B2 | Inhibitors of SARM1 | DISARM THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-110294779-B | Organometallic compound, organic light emitting device including the same, and electronic device | 三星显示有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230374022-A1 | INHIBITORS OF PARG | 858 THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| EP-3544075-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-10-11 | — | — | EP | disclosed |
| EP-3544075-B1 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ORGANIC LIGHT-EMITTING APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-10-11 | — | — | EP | disclosed |
| US-20230060808-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND ORGANOMETALLIC COMPOUND | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-03-02 | — | — | US | disclosed |
| US-20230041621-A1 | SSTR5 ANTAGONISTS | KALLYOPE, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-115594721-A | Organometallic compound, and light-emitting element and electronic device each including the same | 三星显示有限公司（KR） | 2023-01-13 | — | — | CN | disclosed |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | INCYTE CORPORATION (US) | 2022-11-15 | — | — | US | disclosed |
| US-11171296-B2 | Organometallic compound, organic light-emitting device including the same, and organic light-emitting apparatus including the organic light-emitting device | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-18 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7622583-B2 | Heteroaryl sulfonamides and CCR2 | CHEMOCENTRYX, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | LEO PHARMA A/S (DK) | 2007-10-18 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374022-A1 | INHIBITORS OF PARG | PARG, PLG, SERPINB1 | ALDH1A1 4379/4885HPGD 45/4885ALOX15 1188/4885 |
| US-20100041717-A1 | N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES | CETP, APOB, CES1 | ALDH1A1 1722/4885HPGD 2954/4885ALOX15 1794/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | ALDH1A1 1867/4885HPGD 4010/4885ALOX15 2576/4885 |
| US-20100056509-A1 | HETEROARYL SULFONAMIDES AND CCR2 | CCR2, CXCR2, CCR1 | ALDH1A1 2327/4885HPGD 1971/4885ALOX15 1002/4885 |
| US-12043613-B2 | Inhibitors of SARM1 | SARM1, SMN1; SMN2, SARNP | ALDH1A1 4157/4885HPGD 4393/4885ALOX15 4085/4885 |
| US-11171296-B2 | Organometallic compound, organic light-emitting device including the same, and organic light-emitting apparatus including the organic light-emitting device | OCIAD1, ORC3, ORMDL3 | ALDH1A1 24/4885HPGD 3141/4885ALOX15 594/4885 |
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | ALDH1A1 1572/4885HPGD 2069/4885ALOX15 1297/4885 |
| US-20070244117-A1 | Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof | F9, F12, HDAC9 | ALDH1A1 804/4885HPGD 301/4885ALOX15 2264/4885 |
| US-20230041621-A1 | SSTR5 ANTAGONISTS | SSTR5, GLP1R, GPR119 | ALDH1A1 2825/4885HPGD 2011/4885ALOX15 958/4885 |
| US-11498926-B2 | Tricyclic heterocycles as BET protein inhibitors | BRD1, BRD3, BRD2 | ALDH1A1 4459/4885HPGD 1100/4885ALOX15 4113/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | ALDH1A1 699/4885HPGD 142/4885ALOX15 2220/4885 |
| US-20230060808-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND ORGANOMETALLIC COMPOUND | LAGE3, LEF1, ELP1 | ALDH1A1 14/4885HPGD 2365/4885ALOX15 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.